These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38960100)

  • 1. The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate.
    Wensel D; Gartland M; Beloor J; Shetty KN; Wolf J; Stewart E; Clark A; Tenorio A; Krystal M
    Antiviral Res; 2024 Sep; 229():105953. PubMed ID: 38960100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
    Gartland M; Arnoult E; Foley BT; Lataillade M; Ackerman P; Llamoso C; Krystal M
    J Antimicrob Chemother; 2021 Oct; 76(11):2958-2964. PubMed ID: 34297843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
    Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J
    J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
    Wang HG; Williams RE; Lin PF
    Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
    Brower ET; Schön A; Freire E
    Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.
    Richard J; Prévost J; Bourassa C; Brassard N; Boutin M; Benlarbi M; Goyette G; Medjahed H; Gendron-Lepage G; Gaudette F; Chen HC; Tolbert WD; Smith AB; Pazgier M; Dubé M; Clark A; Mothes W; Kaufmann DE; Finzi A
    Cell Chem Biol; 2023 May; 30(5):540-552.e6. PubMed ID: 36958337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals.
    Lepore L; Fabrizio C; Bavaro DF; Milano E; Volpe A; Lagioia A; Angarano G; Saracino A; Monno L
    J Antimicrob Chemother; 2020 Jun; 75(6):1580-1587. PubMed ID: 32191306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins.
    Zoubchenok D; Veillette M; Prévost J; Sanders-Buell E; Wagh K; Korber B; Chenine AL; Finzi A
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.
    Bouba Y; Berno G; Fabeni L; Carioti L; Salpini R; Aquaro S; Svicher V; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Antimicrob Chemother; 2020 Jul; 75(7):1778-1786. PubMed ID: 32160290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage.
    Boutin M; Medjahed H; Nayrac M; Lotke R; Gendron-Lepage G; Bourassa C; Sauter D; Richard J; Finzi A
    Viruses; 2023 May; 15(5):. PubMed ID: 37243275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
    Zhang W; Godillot AP; Wyatt R; Sodroski J; Chaiken I
    Biochemistry; 2001 Feb; 40(6):1662-70. PubMed ID: 11327825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
    Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
    J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.